Granulocyte-Macrophage Colony-Stimulating Factor Upregulates Reduced 5-Lipoxygenase Metabolism in Peripheral Blood Monocytes and Neutrophils in Acquired Immunodeficiency Syndrome
Open Access
- 1 December 1999
- journal article
- Published by American Society of Hematology in Blood
- Vol. 94 (11), 3897-3905
- https://doi.org/10.1182/blood.v94.11.3897.423k12_3897_3905
Abstract
Leukotrienes (LT) are mediators derived from the 5-lipoxygenase (5-LO) pathway, which play a role in host defense, and are synthesized by both monocytes (peripheral blood monocyte [PBM]) and neutrophils (PMN). Because 5-LO metabolism is reduced in alveolar macrophages and PMN from acquired immunodeficiency syndrome (AIDS) subjects, we investigated the synthesis of LT by PBM and PMN from these subjects. There was a reduction (74.2% ± 8.8% of control) in LT synthesis in PBM from human immunodeficiency virus (HIV)-infected compared with normal subjects. Expression of 5-LO (51.2% ± 8.8% of control), and 5-LO activating protein (FLAP) (48.5% ± 8.0% of control) was reduced in parallel. We hypothesized that this reduction in LT synthetic capacity in PBM and PMN was due to reduced cytokine production by CD4 T cells, such as granulocyte-macrophage colony-stimulating factor (GM-CSF). We treated 10 AIDS subjects with GM-CSF for 5 days. PBM 5-LO metabolism ex vivo was selectively increased after GM-CSF therapy and was associated with increased 5-LO and FLAP expression. PMN leukotriene B4(LTB4) synthesis was also augmented and associated with increased 5-LO, FLAP, and cytosolic phospholipase A2 expression. In conclusion, as previously demonstrated for PMN, PBM from AIDS subjects also demonstrate reduced 5-LO metabolism. GM-CSF therapy reversed this defect in both PBM and PMN. In view of the role of LT in antimicrobial function, cytokine administration in AIDS may play a role as adjunct therapy for infections.Keywords
This publication has 33 references indexed in Scilit:
- Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils.Journal of Clinical Investigation, 1998
- Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonistBiochemical Pharmacology, 1995
- The Effects of a 5-Lipoxygenase Inhibitor on Asthma Induced by Cold, Dry AirNew England Journal of Medicine, 1990
- Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factorThe Journal of Pediatrics, 1990
- Phagocytosis and bactericidal action of mouse peritoneal macrophages treated with leukotriene B4International Journal of Immunopharmacology, 1989
- Classification System for Human T-Lymphotropic Virus Type III/ Lymphadenopathy-Associated Virus InfectionsAnnals of Internal Medicine, 1986
- The Role of Mononuclear Phagocytes in HTLV-III/LAV InfectionScience, 1986
- ARACHIDONIC ACID METABOLISMAnnual Review of Biochemistry, 1986
- Infection of monocyte/macrophages by human T lymphotropic virus type III.Journal of Clinical Investigation, 1986
- The nature and action of granulocyte-macrophage colony stimulating factorsBlood, 1980